-
Debate weighs whether BMI should remain central to obesity diagnosis
Francesco Rubino, MD, spoke in favor of moving beyond body mass index in diagnosing obesity. Leigh Perreault, MD, defended the long-time cornerstone of obesity diagnosis.
-
Outstanding Scientific Achievement Award lecturer highlights evolution of unimolecular therapies
Timo D. Müller, PhD, shared his insights on hormonal control of metabolism by glucose-dependent insulinotropic polypeptide (GIP) and next-generation incretin-based polyagonists during a session recognizing his contributions to diabetes and metabolic research.
-
Oral small-molecule GLP-1 RA improves blood glucose and weight reduction
The VISTA and SOLSTICE phase 2b trials evaluated the use of the glucagon-like peptide-1 receptor agonist (GLP-1 RA) elecoglipron in adults. Melanie Davies, CBE, MBChB, MD, FRCP, FRCGP, FMedSci, and Vanita R. Aroda, MD, shared the latest study data.
-
ACHIEVE results show A1C reduction, weight loss in type 2 diabetes
Investigators aim to use orforglipron to address the limitations of injectable GLP-1 RAs. The primary goal is to provide an alternative that meets health needs without the logistical challenges of current treatments, said Rodolfo J. Galindo, MD.
-
Experts share the latest updates on the Standards of Care in Overweight and Obesity
The growing document provides evidence-based, unified guidance and actionable recommendations. Leigh Perreault, MD, presented a new chapter on screening diagnosis. Louis J. Aronne, MD, FACP, shared a new chapter on obesity medications.
-
Expert panel addresses GLP-1 RAs’ factors, features, and future
Amid increasing attention for GLP-1 RAs, a panel of experts summarized a broad spectrum of topics related to these medications, including emerging pharmacological options, muscle physiology, obesity treatment for osteoarthritis, and nutritional counseling.
-
Glucagon/GLP-1 receptor dual agonist demonstrates efficacy for obesity and MASLD
Matthias H. Tschöp, MD, and other researchers detailed phase 3 results of SYNCHRONIZE-1 and SYNCHRONIZE-MASLD showing that survodutide leads to significant weight loss, reduction in liver fat, and other health improvements.
-
REIMAGINE trials demonstrate efficacy of combination therapy for treating type 2 diabetes
Donna Ryan, MD, and other panelists reported on new data from phase 3 trials evaluating the combination of cagrilintide, which mimics amylin, and semaglutide, a glucagon-like peptide-1 receptor agonist, in adults.
-
Innovation Challenge elevates creative solutions to diabetes challenges
Leaders of three start-up ventures pitched their novel product ideas at the Scientific Sessions and exited with connections for opportunities to accelerate their visions for redefining diabetes care and treatment.
-
Triple-hormone therapy demonstrates efficacy for type 2 diabetes and obesity
Activation of the glucagon receptor with retatrutide is being investigated in a large phase 3 program that includes 14 trials and more than 22,000 participants. Researchers, including Ania Jastreboff, MD, PhD, shared data from two of the trials, TRANSCEND-T2D-1 and TRIUMPH-1.